<DOC>
	<DOCNO>NCT01588990</DOCNO>
	<brief_summary>This open-label , prospective , single-arm , multicenter study evaluate relationship marker inflammation progression-free survival patient previously untreated metastatic colorectal cancer . The study consist two phase : Phase A treatment : XELOX plus Avastin ( bevacizumab ) , mFOLFOX6 plus Avastin administer first disease progression . Patients continue Phase B treatment : FOLFIRI plus Avastin second disease progression . The anticipated time study treatment 4 year .</brief_summary>
	<brief_title>A Translational Study Avastin ( Bevacizumab ) Patients With Metastatic Colorectal Cancer ( ASCENT )</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Resected primary tumor patient , patient primary tumor situ : Adult patient , &gt; /= 18 year age Previously untreated metastatic colorectal cancer candidate curative resection WHO performance status 01 Life expectancy &gt; /= 3 month Eligible XELOX , mFOLFOX6 , FOLFIRI Avastin treatment accordance local standard care pharmaceutical benefit scheme Additional inclusion criterion patient primary tumor situ : Intact primary tumor colon rectum require surgical intervention prior study start Minimal asymptomatic primary tumor Resected primary tumor patient , patient primary tumor situ : Previous chemotherapy metastatic colorectal cancer Previous neoadjuvant adjuvant chemotherapy le 6 month prior study start Radiotherapy within 28 day prior enrolment recover radiotherapy History noncolorectal cancer ( patient eligible diseasefree 5 year risk recurrence deem low ) Presence active inflammatory bowel disease History gastrointestinal perforation Peritoneal disease History significant bleeding event Significant vascular disease Peripheral arterial thrombosis thrombotic event within 6 month study start Additional exclusion criterion patient primary tumor situ : Prior endoscopic management current tumor Acute diverticulitis Presence intraabdominal abscess Active gastroduodenal ulcer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>